Positive Data for Hepatitis C Drugs Presented by Gilead, AbbVie Bode Well for Patients
News
Gilead Sciences recently announced that clinical trials involving a pan-genotypic protease inhibitor demonstrated promise in the treatment of a rare hepatitis C (HVC) patient population. The results were presented at The International Liver Congress (2016 ... Read more